YOPD patients were less often than LOPD patients treated with any form of Levodopa, and there was higher use of dopamine agonists, MAO-B inhibitors and amantadine, but less use of cognitive enhancers (p < 0.001). The gene discussed is MAOB; the disease is young-onset Parkinson disease.